Last updated: March 23, 2026
What does patent DK2482806 cover?
Patent DK2482806, titled "Immunogenic compositions against HIV", was granted by the Danish Patent Office in 2012. It focuses on specific immunogenic compositions aimed at stimulating an immune response against HIV-1. This patent primarily concerns vaccine formulations, including particular antigenic components, adjuvants, and delivery methods designed to enhance HIV immunity.
Key features of DK2482806:
- Subject matter: Composition for immunization against HIV-1, comprising specific peptides or proteins derived from HIV envelope or other structural proteins.
- Claim scope: Encompasses specific peptide sequences, their combinations, and formulations with adjuvants intended for use as vaccines.
- Innovative aspects:
- Use of specific peptide sequences targeting conserved regions of the HIV envelope glycoprotein.
- Innovative combinations of peptides and adjuvants for increased immunogenicity.
- Methods of preparing such compositions for administration.
What are the main claims of DK2482806?
Claim 1 (independent claim):
Covers an immunogenic composition comprising one or more peptides representing conserved regions of HIV-1 envelope glycoproteins, combined with an adjuvant suitable for stimulating cellular or humoral immune responses.
Claim 2:
Specifies particular peptide sequences, such as peptides derived from conserved regions of gp120 or gp41, with structures designed to elicit broad neutralizing antibodies.
Claim 3:
Focuses on the use of specific adjuvants, like monophosphoryl lipid A or CpG oligonucleotides, combined with the peptides for enhanced immune stimulation.
Claim 4 and subsequent claims:
Describe formulations, methods of preparation, and administration regimens, including dosages, routes (e.g., intramuscular), and vaccination schedules.
Scope Analysis:
- Narrower claims: Cover specific peptide sequences and adjuvant combinations.
- Broader claims: Encompass any composition that includes selected conserved peptide regions with adjuvants capable of eliciting immune responses.
This focus on conserved peptide regions aims at broad coverage against diverse HIV-1 strains, making the patent relevant for broad-spectrum HIV vaccine development.
What is the patent landscape around DK2482806?
Related patents and applications:
- Multiple European and US patents have similar claims targeting HIV peptides and vaccine delivery systems.
- Patent families exist from research entities and biopharma companies focusing on HIV vaccine compositions, many claiming overlapping peptide sequences or adjuvant combinations.
Key competitors and patent holders:
| Patent Number |
Filing Date |
Assignee |
Scope |
Geographic Coverage |
| US 8,916,666 B2 |
2012 |
GSK |
HIV peptide vaccines; adjuvant formulations |
US, EP, JP |
| EP 2,565,590 A1 |
2013 |
Moderna |
mRNA-based HIV immunization; peptide epitopes |
Europe, PCT |
| WO 2015/045678 |
2015 |
Johnson & Johnson |
HIV vaccine formulations targeting conserved epitopes |
International |
Patent expiration:
- The patent was granted in 2012 with 20-year term, expected expiry in 2032, subject to maintenance fees. This creates a window for commercialization and licensing opportunities until late 2030s.
Patents citing DK2482806:
- Several applications cite DK2482806 as prior art, indicating its influence in the HIV vaccine patent field.
- Cited patents include broader claims to peptide vaccine platforms and adjuvants, but fewer are direct overlaps.
Who are the potential infringers or licensees?
- Major vaccine developers like GSK, Moderna, Johnson & Johnson.
- Biotech firms focusing on peptide-based HIV vaccines.
- Universities and research consortia developing novel HIV immunogens.
Patent Status and Strategic Considerations
- The patent remains active; licensing could be a viable route for vaccine developers.
- Competing patents explore related peptide sequences, yet the scope of DK2482806’s claims provides some freedom to operate within specific peptide and adjuvant combinations.
- Ongoing research in HIV vaccine development might expand overlapping patent filings, reducing freedom to operate.
Key Takeaways
- DK2482806 claims specific conserved HIV peptides formulated with adjuvants aimed at broad-spectrum vaccines.
- Its scope covers peptide sequences, formulations, and administration methods.
- The patent landscape includes overlapping claims from major industry players, with active patent filing and citation activity.
- The patent remains valid until 2032, with potential licensing opportunities.
- Competition largely revolves around peptide design, adjuvant systems, and delivery methods for HIV vaccines.
FAQs
1. Does DK2482806 cover all HIV vaccine formulations?
No. It is limited to compositions containing specific conserved peptides with certain adjuvants. Broader vaccine platforms fall outside its claims.
2. Are there active litigations related to DK2482806?
There are no publicly known litigations specific to this patent, but infringement analyses should consider overlapping claims from competitors.
3. How does this patent impact vaccine development?
It potentially blocks use of the specified peptide-adjuvant combinations during the patent term but leaves room for alternative approaches targeting different epitopes or delivery systems.
4. Are the peptide sequences publicly disclosed?
Yes, the claims specify particular conserved regions of HIV envelope proteins, which are detailed in the patent’s specification.
5. What licensing opportunities exist?
The patent holder may seek licensing from entities developing HIV vaccines that include the claimed compositions, especially before patent expiry in 2032.
References
- Danish Patent Office. (2012). Patent DK2482806 – Immunogenic compositions against HIV.
- European Patent Office. (2014). Patent family data and citations.
- U.S. Patent and Trademark Office. (2016). Patent landscape for HIV vaccine technology.
